Weight loss
Diabetes: GI Dynamics pulls in $35M tranche in $52M round
GI Dynamics (ASX:GID) said it’s pulled in nearly $35 million as part of a $52 million funding round it’s planning to use to back a U.S. trial of its EndoBarrier device.
The Lexington, Mass.-based medical device company said in a regulatory filing that it’s drummed up $34.8 million from 13 unnamed investors.
Weight loss: FDA accepts EnteroMedics’ submission of VBLOC neurostim implant
Weight loss: GI Dynamics raises $52M, announces share purchase plan
GI Dynamics (ASX:GID) said it’s raised roughly $52.2 million (A$57.5 million) in a private placement and is offering another $2.3 million (A$2.5 million) in a stock purchase plan for existing shareholders.
Weight loss: EnteroMedics submits Maestro nerve-blocking implant for FDA review
Neurostimulation devices maker EnteroMedics (NSDQ:ETRM) officially submitted its pre-market approval application to the FDA for review of the Maestro VBLOC neuro-blocking system in treatment of obesity, metabolic diseases and other gastrointestinal disorders.
Weight loss: France bankrolls EndoBarrier cost trial for GI Dynamics
French regulators will fund a trial looking at the cost and utility of the EndoBarrier device for Type II diabetes and weight loss made by GI Dynamics (ASX:GID).
Weight loss: GI Dynamics adds centers in Europe
GI Dynamics (ASX:GID) said another 5 medical centers in Europe are online with its EndoBarrier weight loss and diabetes device.
The Lexington, Mass.-based medical device company said centers in Spain, Switzerland and 3 in Germany are now implanting the device, a gut liner designed to inhibit the uptake of nutrients from food.
Weight loss: GI Dynamics’ U.S. clinical trial taxes its coffers
Investors Down Under shied away from weight-loss devices maker GI Dynamics (ASX:GID) today after president & CEO Stuart Randle told shareholders that the company may need to raise new funds in order to support its clinical trials.
Weight loss: EnteroMedics plans on Q1 PMA submission for Maestro device
EnteroMedics (NSDQ:ETRM) said it expects to submit a pre-market approval application to the FDA this quarter for its Maestro rechargeable vagal blocking therapy to treat obesity.
Chris Christie, Dick Cheney and the power of celebrity endorsements for medical devices
When the New York Post broke the story this week that New Jersey governor and presidential hopeful Chris Christie had underwent weight loss surgery using the LAP-BAND in February some on Wall Street bemoaned the rotund politicians timing.
Weight-loss: New Jersey governor Christie reveals secret Lap-Band surgery | MassDevice.com On Call
MASSDEVICE ON CALL — New Jersey Governor Chris Christie (R) underwent secret Lap-Band surgery to help him lose weight, he revealed to the New York Post this week.
Some analysts suggested that the move signals that Christie is looking at a run for the White House, but the Christie, how has come under fire for his physique on more than 1 occasion, insisted that the surgery was prompted by concern for his health and the urging of his family.